Genprex Issues Stockholder Letter and Provides 2025 Corporate Update

Company Achieves Multiple Clinical Development Milestones in 2025Patient Treatment Continues in Two Lung Cancer Clinical TrialsAUSTIN, Texas, Aug. 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has issued a stockholder letter and corporate update summarizing the Company's recent achievements across its oncology and diabetes pro ...